SCHEMBL6500930

SCHEMBL6500930

CCc1ccc(-c2ccc(Cl)cc2)c(C(=O)Nc2ccc(NCCc3ccccn3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.51
CTNNB1 P35222 2/20 0.48
TCF7L2 Q9NQB0 2/20 0.48
KDM4E B2RXH2 3/20 0.47
HPGD P15428 1/20 0.47
GAA P10253 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
RAB9A P51151 5/20 0.44
ALDH1A1 P00352 2/20 0.44
TP53 P04637 1/20 0.43
NPC1 O15118 5/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 2/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 1/20 0.43
MAPT P10636 1/20 0.43
NR3C1 P04150 2/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
PPARG P37231 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498179 0.93 RAB9A (0.47) CNR1CTNNB1TCF7L2KDM4EHPGD
SCHEMBL6487331 0.92 MEN1 (0.49) CTNNB1TCF7L2KDM4EHPGDGAA
SCHEMBL6500397 0.92 CTNNB1 (0.47) CTNNB1TCF7L2KDM4EHPGDGAA
SCHEMBL6488474 0.92 CNR1 (0.57) CNR1CTNNB1TCF7L2KDM4EHPGD
SCHEMBL6501416 0.89 SMO (0.51) HPGDALDH1A1TP53MEN1LMNA
SCHEMBL6499473 0.89 CTNNB1 (0.53) CNR1CTNNB1TCF7L2KDM4EHPGD
SCHEMBL6488828 0.88 CNR1 (0.51) CNR1CTNNB1TCF7L2KDM4EHPGD
SCHEMBL6497186 0.88 CNR1 (0.53) CNR1CTNNB1TCF7L2KDM4EHPGD
SCHEMBL7085345 0.88 CNR1 (0.55) CNR1CTNNB1TCF7L2KDM4EHPGD
SCHEMBL6489529 0.88 AURKA (0.51) CNR1CTNNB1TCF7L2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 CNR1 102/4885CTNNB1 1793/4885TCF7L2 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.